Laura Towart, Founder and CEO at Vivan Therapeutics, shared a post by Vivan Therapeutics, adding:
“Please join us for our upcoming webinar “Matching a Patient’s Unique Tumor Profile with a Safe, Effective Therapy Combination” Monday, March 9th at 6PM GMT (London).
Vivan Therapeutics’s Chief Scientific Officer, Dr. Nahuel Villegas will lead the discussion, alongside leading GI Medical Oncologist Dr. Daniel Krell HCA Healthcare UK, Royal Free London NHS Foundation Trust.
Quoting Vivan Therapeutics‘s post:
“Please join our upcoming webinar March 9, 2026 at 6:00 PM GMT to learn about our personalized cancer therapeutics services, specifically focusing on TuMatch, a software for rapid, personalized GI cancer treatment recommendations. We utilize a comprehensive genomics-based dataset capturing the full mutational landscape of tumors generated through whole animal disease modeling to generate personalized cancer treatment recommendations. Our original technology platform was developed at and exclusively licensed in partnership with Icahn School of Medicine at Mount Sinai New York.
Vivan Therapeutics’s Chief Scientific Officer, Dr. Nahuel Villegas will lead the discussion, alongside leading GI Medical Oncologist Dr. Daniel Krell of HCA Healthcare UK, Royal Free London NHS Foundation Trust, moderated by Vivan’s CEO Laura Towart.”
Other articles featuring Laura Towart on OncoDaily.